Research

Hormonal

Statin therapy induces skeletal muscle toxicity and atrophy by upregulating the muscle-specific ubiquitin ligase atrogin-1/MAFbx, which mediates increased protein breakdown via the ubiquitin-proteasome pathway.

If you experience muscle pain or weakness while taking statins, it may not be 'in your head' but a specific biological response involving muscle breakdown proteins (atrogin-1). Do not simply stop the medication without consulting your doctor. Discuss testing for muscle enzymes (CK) and potential strategies to mitigate this, such as CoQ10 supplementation or switching to a less lipophilic statin, as the paper suggests these mechanisms are linked to mitochondrial function and specific gene expression.

GoodSupportsHIGH confidence
Collectively, our human, animal, and in vitro findings shed light on the molecular mechanism of statin-induced myopathy and suggest that atrogin-1 may be a critical mediator of the muscle damage induced by statins.
Jun‐ichi Hanai et al. · Journal of Clinical Investigation · 2007

Why this rating

The study combines human biopsy data, in vitro cell culture, and in vivo zebrafish models with genetic knockdown/knockout evidence, providing strong mechanistic causality.

Source

The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity

Jun‐ichi Hanai et al. · Journal of Clinical Investigation · 2007

DOI 10.1172/jci32741

mechanism_only · n=19Cited 284×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →